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Abstract 
Objective and design 
Prostaglandin D2 (PGD2) has been shown to cause eosinophil, basophil and Th2 cell 
chemotaxis in vitro and in vivo through an action on the prostaglandin CRTH2 
receptor.  In the present study, the dependence of PGD2-induced eosinophil 
accumulation in vivo on interleukin-5 (IL-5) blood eosinophilia was investigated.   
Materials 
Guinea-pigs were exposed to aerosols of 13,14di-hydro 15-keto PGD2 (DK-PGD2) or 
platelet activating factor (PAF) and the eosinophil content of the bronchoalveolar 
lavage fluid or blood determined.  In some experiments, DK-PGD2 was administered 
systemically and eosinophilia measured. 
Results 
Aerosols of DK-PGD2 caused eosinophil accumulation in the lungs 24h after 
exposure.  DK-PGD2 (10g.ml
-1
)-induced airway eosinophilia was inhibited when 
animals were treated with the CRTH2 receptor antagonist ramatroban.  1-4h after 
exposure to DK-PGD2 a significant decrease in blood eosinophil count was measured.  
The anti-IL-5 antibody TRFK-5 had no inhibitory effect of DK-PGD2-induced airway 
eosinophilia, but abolished airway eosinophilia induced by exposure of guinea-pigs to 
aerosols of PAF.  Intracardiac injection of DK-PGD2 induced a dose-related increase 
in blood eosinophil numbers.   
Conclusions 
It is concluded that, in the guinea-pig, DK-PGD2-induced airway eosinophilia is 
mediated by an action on prostaglandin CRTH2 receptors and that this response 
appears to be independent of IL-5. 
Introduction 
Evidence has accumulated suggesting that prostaglandin D2, released by mast cells, 
may be involved in allergic inflammation through an action on the CRTH2/DP2 
receptor[1].  This G protein coupled receptor is expressed on eosinophils, 
lymphocytes and basophils [2] and, in common with other chemoattractant receptors, 
mediates cell activation through an action involving Gi [1].   
 
Prostaglandin D2 (PGD2) causes eosinophil and lymphocyte chemotaxis in vitro 
through an action on the CRTH2 receptor [3-5].  In addition, 13,14di-hydro 15-keto 
PGD2 (DK-PGD2), a PGD2 metabolite, is a selective agonist at the CRTH2 receptor, 
has a markedly lower affinity for the DP1 receptor and is a potent activator of cells 
bearing these receptors [6].   
 
Studies in laboratory animals have shown that PGD2 administration augments 
antigen-induced airway inflammation [7] and induces eosinophil accumulation in the 
airways of rats primed with interleukin-5 [8].  Furthermore, CRTH2 knockout mice 
have a reduced inflammatory response to IgE induced inflammation of the skin [8]and 
to cedar pollen-induced dermatitis [9].  In addition, the prostaglandin CRTH2 receptor 
antagonist ramatroban inhibits eosinophil migration in vitro and in vivo, and is used in 
the treatment of allergic rhinitis in Japan [10].  Thus, it has been proposed that 
antagonists of the prostaglandin CRTH2 receptor may have therapeutic utility in the 
treatment of allergic disease [2].   
 
However, other agents, including a range of chemokines, platelet activating factor 
(PAF) and histamine, also induce eosinophil recruitment [11-14] and antagonists of 
these agents may also have utility in the treatment of allergic inflammation.   
 
Interleukin-5 (IL-5) causes blood eosinophilia [15] and may be central to eosinophil 
recruitment in disease.  Thus, in order for eotaxin to induce eosinophil recruitment 
into the lung and skin a blood eosinophilia, induced by IL-5, is necessary [15].  
Furthermore, in laboratory animals antigen- and PAF- induced airway eosinophilia 
was inhibited when animals are pre-treated with an antibody to IL-5 demonstrating 
the dependence of eosinophil accumulation on this cytokine [16-19].   
 In asthmatic patients, an antibody to IL-5, mepolizumab, caused a small reduction in 
blood eosinophil numbers and decreased antigen-induced eosinophil recruitment into 
the lungs but this treatment failed to inhibit antigen-induced late-phase 
bronchoconstriction. [20].  In a further analysis, mepolizumab caused a partial 
reduction in mucosal eosinophil numbers, suggesting that partial inhibition may be 
insufficient for a clinical effect [21].  One possible explanation for this observation is 
that, in man, mediators other than IL-5 contribute to the maintenance of eosinophilia.  
Such a factor could be PGD2, which has been shown to increase blood eosinophil 
counts in laboratory animals through an action on CRTH2 and DP receptors [22, 23]. 
 
In the present study the ability of the prostaglandin CRTH2 receptor agonist 13,14 di-
hydro, 15-keto prostaglandin D2 (DK-PGD2) [6, 22] to induce eosinophilia in guinea-
pig lungs and the dependence of any eosinophilia on IL-5 was investigated. 
Method 
Materials 
13,14 di-hydro, 15-keto prostaglandin D2 (DK-PGD2) and ramatroban were purchased 
from Cayman Chemical (Axxora (UK) Ltd., Nottingham, UK).  Platelet activating 
Factor (PAF), heparin and dextran (MW 500,000) were purchased from Sigma-
Aldrich, Poole, Dorset, UK.  TRFK-5 was purchased from R&D systems Ltd., 
Abingdon, UK. 
 
Eosinophilia in Guinea-pig airway and blood 
Female Dunkin Hartley guinea-pigs (250-350 g) were purchased from Darley Oaks 
Farm, Newchurch, UK.  Animals were housed and all experiments conducted under a 
project licence granted under the Animals (Scientific Procedures) Act 1986.  Groups 
of guinea-pigs were placed in a plastic chamber and exposed to aerosols of PAF or 
DK-PGD2, generated from a nebuliser (DeVilbiss) driven by a compressor (DeVilbiss 
Pulmostar), for 10 min.  In experiments where guinea-pigs were treated with the anti-
IL-5 antibody TRFK-5, this antibody was administered by intraperitoneal injection in 
PBS (1 ml.kg
-1
) 30 min prior to exposure of animals to aerosols of PAF or DK-PGD2.  
In these experiments control animals were given an intraperitoneal injection of PBS. 
 
At intervals after exposure to aerosols (usually 24h) animals were killed by an 
overdose of pentobarbitone Na (Euthetal; Merial), the trachea was cannulated and the 
lungs lavaged twice with 5ml heparinised (10 U.ml
-1
) PBS.  A cytocentrifuge 
preparation (Thermo Shandon, cytospin 2) was prepared from an aliquot of the pooled 
bronchoalveolar lavage (BAL) fluid recovered and stained with May Grunwald 
Giemsa stain.  A total leukocyte count was also made from the BAL fluid using a 
haemocytometer. The percentage eosinophils was determined from the cytocentrifuge 
preparation under oil immersion microscopy and the number of eosinophils/ml blood 
determined from this percentage and the total leukocyte count. 
 
In experiments where the number of eosinophils in the blood was determined, animals 
were killed by an overdose of pentobarbitone Na and a blood sample (2 ml) was taken 
into heparin (0.05 ml) by cardiac puncture.  100l of blood was mixed with 900l 
Turk’s solution and the total number of leukocytes determined with a 
haemocytometer.  500 l blood was mixed with 500 l 4% Dextran (mol wt 500,000; 
Sigma) and the red cells allowed to sediment.  A cytocentrifuge preparation was 
prepared from the leukocyte rich supernatant and stained with May Grunwald Giemsa 
stain (Sigma).  The percentage eosinophils was determined from the cytocentrifuge 
preparation and the number of eosinophils/ml blood determined from this percentage 
and the total leukocyte count. 
 
Data analysis 
Each experiment was performed with groups of 2-4 animals and repeated to give the 
group sizes stated once data were pooled.  Pooled data were analysed by ANOVA 
followed by Dunnett’s post hoc test [24] using commercially available software 
(Prism; GraphPad, San Diego, California).  A difference between groups was taken to 
be statistically significant when P<0.05. 
 
Results 
 
DK-PGD2-induced airway eosinophilia 
When the lungs of guinea-pigs were lavaged twice with 5 ml PBS, 7-8 ml of 
bronchoalveolar lavage fluid was recovered.  The volume of BAL recovered was not 
affected by any of the treatments used.  Bronchoalveolar lavage fluid from untreated 
guinea-pigs contained 8.76 x 10
4
 ± 1.6 x 10
4
 (n=9) eosinophils.ml
-1
 (Figure 1).  
Exposure of guinea-pigs to aerosols generated from solutions of DK-PGD2 (0.1 to 100 
g.ml-1) caused a small concentration-related accumulation of eosinophils in the 
airway, 24h after exposure to aerosols (Figure 1).  Aerosols generated from solutions 
of DK-PGD2 greater than 0.1 g.ml
-1
 caused a significant (P<0.05) eosinophil 
accumulation that appeared to be maximal when a concentration of 10 g.ml-1 was 
used (Figure 1). DK-PGD2-induced eosinophil accumulation was also time-
dependent.  Following exposure to an aerosol of 10g.ml-1 DK-PGD2 no significant 
(P>0.05) eosinophilia was detected 2 and 6h after exposure of animals whereas by 
24h significant eosinophilia (P<0.05) was observed (Figure 2).  While a small 
increase in eosinophil numbers in the recovered BAL was measured 18h after 
exposure to an aerosol of DK-PGD2, this increase was not statistically significant 
(P>0.05). 
 
In a separate experiment, guinea-pigs were exposed to aerosols generated from 
solutions of DK-PGD2 (10 g.ml
-1
) and blood samples taken at intervals after 
exposure, a significant (P<0.05) decrease in blood eosinophil count was seen 1-4h 
after exposure to aerosols of DK-PGD2 (Figure 3).  However, this eosinopenia 
recovered and 6h after exposure no significant (P>0.05) change in blood eosinophil 
count was seen (Figure 3). 
 
Effect of ramatroban on DK-PGD2-induced airway eosinophilia 
When guinea-pigs were pretreated with ramatroban (0.1 - 100 g.kg-1 p.o.) 30 min 
prior to being exposed to an aerosol of DK-PGD2 (10 g.ml
-1
), a dose-related 
inhibition of DK-PGD2-induced eosinophil accumulation was seen (Figure 4).  Doses 
of ramatroban greater than (1.0 g.kg-1 p.o.) caused a significant (P<0.05) inhibition 
of DK-PGD2-induced eosinophilia.  Furthermore 0.01 mg.kg
-1
 ramatroban reduced 
DK-PGD2-induced BAL eosinophil count to a value that was not significantly 
different (P>0.05) from that seen in untreated animals (Figure 4). 
 
 
Effect of TRFK-5 on DK-PGD2-induced airway eosinophilia 
 
When guinea-pigs were treated with the anti-IL-5 antibody TRFK-5 (100 g.kg-1 i.p.) 
30 min prior to exposure to aerosols of DK-PGD2 (10 g.ml
-1
), no significant 
(P>0.05) inhibition of DK-PGD2-induced eosinophilia was seen (Figure 5A).  In 
contrast, in a separate experiment, the same dose of TRFK-5 significantly inhibited 
airway eosinophilia induced by an aerosol of platelet activating factor (PAF; 100 
g.ml-1)(Figure 5B). 
 
Blood eosinophilia induced by systemic administration of DK-PGD2 
 
Following administration by intracardiac injection, DK-PGD2 (1 – 100 g) caused a 
dose-related blood eosinophilia (Figure 6A).  Doses of DK-PGD2 greater than 1.0 g 
significantly (P<0.05) increased blood eosinophil count 1h after administration 
(Figure 6B).  Blood eosinophilia induced by 10 g DK-PGD2 was evident 30 and 60 
min after administration of DK-PGD2 (Figure 6B). 
Discussion 
The experiments described above show that exposure of guinea-pigs to aerosols of the 
selective prostaglandin CRTH2 receptor agonist DK-PGD2 caused eosinophil 
recruitment in the airways.  This eosinophil accumulation appeared to be mediated 
through an action of DK-PGD2 on the prostaglandin CRTH2 receptor since the effect 
was inhibited when guinea-pigs were treated with the prostaglandin CRTH2 receptor 
antagonist ramatroban prior to exposure to DK-PGD2.  The dose-range over which 
ramatroban inhibited DK-PGD2-induced eosinophil accumulation, in the present 
study, was slightly lower than that used by others to block the CRTH2 receptor in rats 
[23, 25], but this be because a relatively low dose of DK-PGD2 was used.  In the 
present study, a dose-effect curve for ramatroban was obtained and it was noted that 
higher doses produced total inhibition of eosinophilia similar to that obtained by 
others at the lowest dose tested [23, 25].  
 
Ramatroban was originally developed as a thromboxane receptor antagonist and has 
affinity for both TP and CRTH2 receptors [10].  Thus, it is theoretically possible that 
DK-PGD2-induced eosinophilia is mediated via an action on TP receptors.  However, 
eosinophils do not express TP receptors [1] and eosinophilia-induced by DK-PGD2 in 
the rat was unaffected by the specific TP receptor blocking drug SQ29548 but was 
blocked by ramatroban [25].  Thus, it seems unlikely that TP receptors contribute to 
DK-PGD2-induced eosinophilia and its inhibition by ramatroban. 
 
The finding that DK-PGD2 induced airway eosinophilia in guinea-pigs after aerosol 
administration is consistent with data reported by others in rats [26].  However, in 
some studies in the rat [25] DK-PGD2-induced airway eosinophilia only after a blood 
eosinophilia was induced by intravenous administration of IL-5.  In contrast to 
laboratory rats, guinea-pigs often have a higher resting blood eosinophil count.  Thus, 
one explanation for the finding that in the guinea-pig DK-PGD2-induced airway 
eosinophil accumulation without the need for a treatment to induce blood eosinophilia 
is that the animals had a pre-existing blood eosinophilia that is not present in rats. 
 
The anti IL-5 antibody, TRFK-5, has been widely used to show a role for IL-5 in 
allergen induced airway inflammation in experimental animals, including guinea-pigs 
[16-18, 27].  This antibody has also been used to show that eosinophil accumulation 
in the airways of guinea-pigs induced by PAF is IL-5 dependent [19].  In the present 
study, TRFK-5 inhibited PAF-induced eosinophilia confirming earlier findings [19] 
but TRFK-5 failed to inhibit eosinophilia induced by DK-PGD2.  These findings 
suggest that, in guinea-pigs, eosinophilia induced by agents that act on the CRTH2 
receptor is independent of IL-5. 
 
It has been proposed that IL-5 recruits eosinophils from the bone marrow to the blood 
and has a “priming” action on these cells such that they can migrate into a lesion 
under the influence of other agents, such as the chemokine eotaxin [15].  In the 
present study, exposure of guinea-pigs to an aerosol of DK-PGD2 caused a fall in 
blood eosinophil numbers shortly after treatment that recovered by 6h after treatment.  
These findings support the findings that DK-PGD2-induced eosinophilia is 
independent of IL-5 and suggest that following inhalation of DK-PGD2, eosinophils 
are directly reruited into the lung from the blood and this results in a decrease in blood 
eosinophils. Subsequently, eosinophils are released from the bone marrow into the 
blood to restore the blood eosinophil count.  In the present study, blood eosinopenia 
was rapid yet eosinophil accumulation in the BAL was only detected 18-24h after 
exposure to aerosols of DK-PGD2.  It is possible that the reason for the delay in 
detecting airway eosinophilia is because eosinophils have to migrate into the airway 
wall before entering the lumen of the airway where they can be recovered by BAL.  
However, further experiments measuring eosinophilia in the lung tissue would be 
necessary in order to resolve this discrepancy. 
 
The findings described in the present study contrast with those of Shichijo et al. who 
reported that intravenous administration of PGD2 and DK-PGD2 caused a rapid 
increase in blood eosinophil counts in rats, mice and guinea-pigs through an action on 
CRTH2 receptors[22].  These authors concluded that DK-PGD2 caused the release of 
eosinophils from the bone marrow, a conclusion confirmed in the guinea-pig by the 
demonstration that PGD2 and DK-PGD2 release eosinophils from the bone marrow of 
perfused guinea-pig hind quarters [23].  Furthermore, in guinea-pigs PGD2-induced 
eosinophilia was mediated by both DP and CRTH2 receptors [23].  However, the 
doses of PGD2 and DK-PGD2 used in these experiments [22] are higher than those 
likely to reach the blood in the present study.  Recent studies [23] in guinea-pig 
perfused hind quarters used a low concentration of DK-PGD2 to release eosinophils 
from the bone marrow.  In these experiments the tissue was perfused with 
physiological salt solution and it is not clear whether or not higher concentrations 
would be necessary to achieve the same response if blood were used as a perfusion 
fluid.  Furthermore, the supposition that insufficient DK-PGD2 reaches the blood in 
the present study is supported by the observation that intravenous administration of 
doses of DK-PGD2 equal to the concentration in the nebuliser used in the present 
study was necessary to induce blood eosinophilia in the experiments described by 
others [22].  Similar findings have been reported by others in rats where intratracheal 
administration of DK-PGD2 induced airway eosinophil accumulation without a blood 
eosinophilia [25].   
 
The finding that DK-PGD2-induced airway eosinophilia is not dependent on IL-5 
may be of therapeutic significance.  Eosinophils are thought to be key effector cells in 
the pathology of allergic inflammation [28, 29] and eosinophil chemoattractants, such 
as eotaxin, act in concert with IL-5 to cause eosinophil recruitment [15, 30].  Thus, a 
model has been proposed where IL-5 acts on the bone marrow to cause a blood 
eosinophilia and to prime these cells while agents such as eotaxin recruit IL-5 primed 
eosinophila from the blood [15].  If such a mechanism were pivotal to the pathology 
of allergic inflammatory diseases then an inhibitor of IL-5 should inhibit eosinophil 
recruitment and alleviate the disorder. 
 
In man a humanised anti-IL-5 antibody, mepolizumab, caused a partial reduction of 
blood eosinophilia in asthmatic patients but did not significantly improve the 
symptoms of asthma [20, 31] suggesting that factors other than IL-5 may contribute to 
the eosinophilia seen in the lungs of asthmatic patients.  One such factor could be 
PGD2 released by the mast cell acting on the CRTH2 receptor.  The CRTH2 receptor 
promotes eosinophil, basophil and Th2 lymphocyte chemotaxis [2] and has recently 
been shown to activate Th2 cells to release many of the cytokines found in asthma 
including IL-5 [32].  Furthermore, ramatroban has therapeutic utility in allergic 
rhinitis suggesting a role for CRTH2 receptors in the pathology of this disorder in 
man.  If eosinophil recruitment mediated by CRTH2 receptor activation in man is also 
independent of IL-5 then the existence of such mechanisms could explain the lack of 
clinical efficacy of preparations such as mepolizumab in the clinic. 
 
In conclusion, the experiments described in the present study show that the CRTH2 
receptor agonist DK-PGD2 induces airway eosinophil accumulation in guinea-pig 
lungs after aerosol administration.  This lung eosinophilia is mediated through an 
action on the CRTH2 receptor and appears to be independent of IL-5.  Because the 
CRTH2 receptor antagonist ramatroban has clinical utility in the treatment of allergic 
inflammation it is suggested that this IL-5 independent pathway may offer an 
explanation for the failure of anti-IL-5 antibodies to produce a clinically beneficial 
effect in the treatment of allergic inflammation in man. 
Figure 1.  Eosinophil accumulation in the airways of guinea-pigs 24h after exposure 
to aerosols of DK-PGD2.  Guinea-pigs were placed in a plastic chamber and exposed 
to aerosols of DK-PGD2 for 10 min.  Bars represent the mean ± s.e.mean of the 
number of eosinophils.ml
-1
 in the BAL recovered from 6 guinea-pigs. 
 
 
Figure 2.  Time course for DK-PGD2-induced airway eosinophilia in guinea-pigs.  
Guinea-pigs were exposed to an aerosol generated from a solution of DK-PGD2 
(10g.ml-1) and the lungs lavaged at the time indicated.  Bars represent the mean ± 
s.e.mean of the number of eosinophils.ml
-1
 in the BAL recovered from 4 guinea-pigs. 
 
 
Figure 3.  Blood eosinopenia induced by aerosols of DK-PGD2 (10g.ml
-1
) in the 
guinea-pig.  Guinea-pigs were exposed to aerosols of DK-PGD2 for 10 min and a 
blood sample taken at the time indicated.  Bars represent the mean ± s.e.mean of the 
number of eosinophils.ml
-1
 in blood samples from 6 guinea-pigs. 
 
 
Figure 4.  Inhibition of DK-PGD2-induced airway eosinophilia in the guinea-pig by 
ramatroban.  Guinea-pigs were dosed with ramatroban orally 30 min prior to exposure 
to an aerosol of DK-PGD2 (10g.ml
-1
).  24h after exposure to DK-PGD2 the 
eosinophil content of the recovered BAL was determined.  Bars represent the mean ± 
s.e.mean of the number of eosinophils.ml
-1
 in the BAL recovered from 6 guinea-pigs. 
 
 
Figure 5.  The effect of the anti-IL-5 antibody TRFK-5 on (A) DK-PGD2-, or (B) 
PAF-induced eosinophil accumulation in guinea-pig lungs.  Guinea-pigs were treated 
with TRFK-5 30 min prior to exposure to an aerosol of DK-PGD2 (10g.ml
-1
) or PAF 
(100g.ml-1).  The number of eosinophils in the recovered BAL was determined 24h 
after exposure to aerosols. Bars represent the mean ± s.e.mean of the number of 
eosinophils.ml
-1
 in the BAL recovered from 6 guinea-pigs. 
 
 
Figure 6.  Blood eosinophilia induced by intracardiac administration of DK-PGD2 to 
guinea-pigs.  (A) Anaesthetised guinea-pigs received an intracardiac injection of DK-
PGD2 (1-100 g) and the blood eosinophil count determined 60 min later.  (B) 
Anaesthetised guinea-pigs received an intracardiac injection of DK-PGD2 (10mg) and 
the blood eosinophil count determined at the time indicated. Bars represent the mean 
± s.e.mean of the number of eosinophils.ml
-1
 of blood from 6 guinea-pigs. 
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